Why, given similar medical circumstances-high familial risk of breast cancer -will some women elect to join a trial of drugs designed to reduce that risk but others choose not to take part? The aim of this study was to identify measurable differences between women who elect to join a placebo-control
To count or not to count? A review of the issue of adequacy in breast FNA
β Scribed by Andrea Abati
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 73 KB
- Volume
- 21
- Category
- Article
- ISSN
- 8755-1039
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
To elucidate the mechanisms responsible for the development of anti-estrogen resistance, we have cloned and established 3 stable ICI-182,780-resistant sub-lines, MCF-7/182 R -1, MCF-7/182 R -6 and MCF-7/182 R -7 from the estrogen-receptor(ER)-positive and estrogen-responsive human breastcancer MCF-7
underwent delivery and definitive surgical treatment. The patients were evaluated of Obstetrics and Gynecology, University of Calduring pregnancy for evidence of a clinical response to chemotherapy. Intraopera-ifornia-Irvine Medical Center, Orange, California. tive findings and pathologic analysis
The Concept of Tenju-gann, or "Natural-End Cancer" T he concept of Tenju-gann proposed by Kitagawa et al. 1 and dis- cussed in the accompanying editorial by Kennedy 2 deserves broader application than these authors suggest. Although cancer is increasingly an illness of the elderly, there remains a
## Abstract ## Objective In Japanese individuals, the β169C/T singleβnucleotide polymorphism (SNP) in __FCRL3__ has been reported to be associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and autoimmune thyroid diseases. The objective of this study was to test the associ